Implicit Bioscience News Today

Acute Respiratory Distress Syndrome (ARDS) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report 2020 to 2030

Acute Respiratory Distress Syndrome (ARDS) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report 2020 to 2030

/PRNewswire/ -- Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the IC14 arm of the trial has been...

/PRNewswire/ -- Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the IC14 arm of the trial has been...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

The video has been deceptively edited.

Brisbane biotech company trials drug on US COVID-19 patients in bid to find new way to prevent people dying of virus ThuThursday 15 updated 33 Professor Ian Frazer has developed an anti-inflammatory drug used to treat COVID-19 patients. ( Print text only Cancel A Brisbane biotech company, led by award-winning immunologist Ian Frazer, has created an anti-inflammatory drug, which is being trialled as a potential treatment for severely-ill COVID-19 patients in the United States. Key points: The dr...

2021-04-16 11:35:50 GMT2021-04-16 19:35:50(Beijing Time) Xinhua English SYDNEY, April 16 (Xinhua) -- A Brisbane and Seattle-based company said on Friday that a new therapeutic candidate for the treatment of COVID-19 patients will enter a clinical trial in the United States, led by Professor Ian Frazer, a former recipient of the Australian of the Year award. Developed by biotechnology company Implicit Bioscience, the drug IC14 will be tested in more than 400 COVID-19 patients in 10 to 15 ...

Health by Janelle Miles Premium Content   A Brisbane companys experimental anti-inflammatory drug is being tested as a potential treatment in COVID-19 patients as part of trials sponsored by the US Government. The drug, IC14, is being administered to Americans admitted to hospital with COVID-19 as part of two separate studies - in people on ventilators admitted to intensive care units and in others before they are ill enough for the ICU. IC14 was invented...

Clinical trial of monoclonal antibody for treating respiratory disease in COVID-19 patients begins A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infecti...